Godrej Agrovet Q2 FY27 Earnings Call: Maintains Double-Digit PBT Guidance, Milk Inflation Weighs on Margins (GODREJAGRO)

Godrej Agrovet Ltd held its Q2 FY27 earnings call on November 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Volume-led revenue growth, but EBITDA flat as inflation bites

• Revenue +17% YoY to Rs.2,995 Cr — Q2 FY 2026-2027 growth driven by higher realizations and volumes across animal nutrition, oil palm and B2C food; PBT +5% to Rs.131 Cr and PAT +22% to Rs.103 Cr.
• EBITDA flat at Rs.222 Cr (7.4% margin) — input inflation across milk, feed and packaging plus geopolitical volatility pressured costs.
• H1 FY 2026-2027 revenue +13% to Rs.5,847 Cr — EBITDA and PBT declined modestly on inflation and adverse weather; H1 PAT at Rs.231 Cr.
• Net working capital improved to 21 days from 32 days in the year-ago period (FY 2025-2026); absolute working capital reduced to Rs.655 Cr.
• Super El Niño dominated the quarter — monsoon ended ~13% below normal and reservoir levels at a 10-year low, creating uncertainty for the rabi season in FY 2026-2027.

Weather-hit OER recovering; double-digit FFB guidance intact

• Q2 FY 2026-2027 OER at ~18.9% — below Q2 FY 2025-2026 due to cyclone disruption and India's driest June in 100 years (~40% rain deficit); the shortfall flowed into the segment's EBIT margin.
• Recovery underway — September 2026 OER recovered to near year-ago levels and October ran marginally ahead; management targets ending FY 2026-2027 at 19.7%+ OER, recovering the hit over the next four months barring further weather shocks.
• Double-digit FFB growth guidance reaffirmed for FY 2026-2027 and FY 2027-2028 — cyclones caused no tree damage (only a few tilted trees) and replenished soil water; 13,000 hectares added in H1 FY 2026-2027.
• AP government FFB price order pending — the FY 2026-2027 GO has not been issued; the FY 2025-2026 order assumed 20.01% OER. Management hopes the new assumed OER comes down (favorable) but called it "anybody's guess" and outside the company's control.
• PKO derivatives plant commissioned 01 Sep 2026 — hydrogenation and fractionation to be added in December 2026 (Q3 FY 2026-2027); meaningful contribution expected from Q4 FY 2026-2027, full scale-up in FY 2027-2028, adding ~2% to oil palm segment EBITDA margin over the midterm (2-3 years).
• Palm prices volatile — down ~5-9% from September highs per the analyst's framing; management expects ~4,250-4,350 range-bound over Q3 FY 2026-2027, potentially creeping up by Feb-Mar 2027 (Q4 FY 2026-2027) depending on El Niño in Indonesia and Malaysia.

El Niño-driven downturn; diversification and CDMO pipeline on course

• Crop care profitability declined — revenue grew on a lower base but El Niño-led demand weakness (cotton hit by June dry heat; August-October also tough) and unfavorable mix hurt; management cites an industry-wide tough agchem year and warns of a tough Rabi season ahead in FY 2026-2027 as reservoir levels have crashed.
• Ashitaka off to a "rock star" start — the maize herbicide is guided to cross Rs.100 Cr revenue in its first year (FY 2026-2027); Takai (multi-crop insecticide) rolled out and soybean herbicide Ghasnaj launched in November 2026 (Q3 FY 2026-2027).
• Targeting 7 crop segments by FY30 (FY 2029-2030) — to sharply reduce dependence on cotton and chili, with 1-2 new pipeline products planned every year.
• Astec CDMO funnel strengthening — ~90% of inquiries converted to the R&D stage in Q2 FY 2026-2027; ~15 products in the R&D pipeline with significant commercializations expected over the next 2-3 years; R&D-stage products convert to commercialization at ~70-80% per Sunil Kataria.
• CDMO mix target — management is targeting CDMO at 50-55% of Astec's business over the midterm (period unspecified).
• Patience advised — management frames the agchem downturn as an unforeseen, weather-driven one-off year; structural transformation of crop care and Astec may take a couple of years.

Milk inflation persists; Foods B2C running ahead of plan

• No milk-price respite in Q3-Q4 FY 2026-2027 — CEO Sunil Kataria emphatically ruled out near-term relief; dairy profitability remains affected by elevated milk procurement, packaging and logistics costs.
• Structural milk-price reset — management attributes inflation to temporary El Niño/heat-stress on cattle productivity plus a structural shift to value-added dairy (paneer/curd need sharply more milk per kg), which it believes "is here to stay"; normalization of the temporary component only from Q1 FY 2027-2028 and only if the next monsoon is normal.
• Godrej Foods B2C revenue +50% — B2C salience rose to 38%; first 6-8 months of FY 2026-2027 running ahead of plan, aided by a frozen-food tailwind from quick-commerce dark stores.
• ~25% of Foods business from products launched in the trailing one year (as of Q2 FY 2026-2027); three bets: frozen chicken, momos and nuggets (market leader; "crispy bites" launched successfully).
• Momos category-building — the Indian momos market is roughly 60% non-veg / 40% veg; first veg momo rolls out in November 2026 (Q3 FY 2026-2027); branded conversion framed as a ~3-year effort through ~FY 2029-2030.
• Dairy GTM revamp — an ~18-month correction to fix clashing parallel channels; "AMPM" distributor pilot launched in Chennai ~a month before the call (Q2 FY 2026-2027), to be assessed over 6 months / 2 quarters (Q3-Q4 FY 2026-2027) before rollout to other cities and Andhra Pradesh/Telangana.

Deliberate broiler deprioritization; ACI Godrej stabilized and re-accelerating

• Animal feed volumes +3% with ~8% price growth — cattle feed +8% and layer feed +15% (priority segments); broiler feed degrew sharply by deliberate choice as management deprioritizes a segment where the industry is 85-90% integrated, any near-term broiler pickup not seen as sustainable.
• B2C shift in poultry/Foods — B2C salience rose from 25% to 35% over the past 3-4 quarters (through Q2 FY 2026-2027); FY 2026-2027 YTD B2C grew ~50% while EBITDA-plus-working-media grew 12%, with margin up from 5.6% in FY 2025-2026 to 5.8% (+20 bps) despite maize and rapeseed hyperinflation.
• Revenue optically muted until B2C salience reaches ~70% (period unspecified) — as the Livebird B2B business is given up; investment calibration "too early right now".
• ACI Godrej (Bangladesh) stabilized — after ~2 years of strikes/unrest, on-ground situation has stabilized; a new CEO was appointed within the last 10 months (as of Q2 FY 2026-2027) and India animal-nutrition R&D expertise is being extended to ACI.
• H1 FY 2026-2027 high double-digit volume growth across every ACI segment — aqua, poultry and dairy; management is "very bullish" on volumes, with commodity inflation the key near-term headwind, which it expects to pass.
• Rs.50 Cr dividend received in Q2 FY 2026-2027 — from the Bangladesh JV ACI Godrej; no other one-offs in Q2 other income (pet food contributed ~Rs.5 Cr, a continuing item).

Double-digit PBT guidance maintained but tougher; sales transformation underway

• FY27 double-digit PBT growth guidance maintained — originally set at the Q1 FY 2026-2027 call; management flagged a tougher environment, with the El Niño impact on agchem hitting harder than expected and clarity improving month by month.
• Oil palm EBITDA CAGR — responding to Abhijit Akella's query citing ~Rs.426 Cr oil palm EBITDA in FY 2025-2026, management guided to a "healthy double-digit" EBITDA CAGR, which it believes it can deliver in FY 2026-2027 itself and over the midterm.
• Debt up ~Rs.200-300 Cr vs March 2026 (FY 2025-2026 close) — CFO Ravishankar attributed this to a proactive inventory build to capture better prices; working capital days improved from 31 to 22 days in Q2 FY 2026-2027, inventory to be consumed in H2 FY 2026-2027, and debt/equity expected at ~0.8x through H2 FY 2026-2027.
• Sales transformation CoE in place — a head hired from Britannia and Marico, with 2 more team members joining by December (Q3 FY 2026-2027) to drive the agenda from FY 2027-2028 onwards; Gaurav joined as new CEO of dairy; new sales teams inducted across Crop Care, Godrej Foods and dairy over the last 12 months (through Q2 FY 2026-2027).
• Extra manpower costs already impacting FY 2026-2027 — annualized impact flows into FY 2027-2028; framed as an investment to be balanced via "pie projects" and premiumization; quasi-GTM models for animal nutrition and crop care aimed for ~FY 2027-2028.
• Sustainability metrics (as of Q2 FY 2026-2027) — renewable energy at 79.3% of the portfolio; Scope 1 and 2 emissions down 11.1%; CDP leadership rating retained; progressing towards SBTi-approved emission targets.